Journal of Clinical and Translational Hepatology

Journal Information
ISSN / EISSN : 22250719 / 23108819
Current Publisher: Xia & He Publishing Inc. (10.14218)
Total articles ≅ 315
Current Coverage
Archived in

Latest articles in this journal

Vivek A Lingiah, Mumtaz Niazi, Raquel Olivo, Flavio Paterno, James V Guarrera, Nikolaos T Pyrsopoulos
Journal of Clinical and Translational Hepatology, Volume 8, pp 1-7; doi:10.14218/jcth.2019.00050

Jie Li, Jian-Gao Fan
Journal of Clinical and Translational Hepatology, Volume 8, pp 1-5; doi:10.14218/jcth.2020.00019

An outbreak of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection (2019 coronavirus disease, COVID-19) since December 2019, from Wuhan, China, has been posing a significant threat to global human health. The clinical features and outcomes of Chinese patients with COVID-19 have been widely reported. Increasing evidence has witnessed the frequent incident liver injury in COVID-19 patients, and it is often manifested as transient elevation of serum aminotransferases; however, the patients seldom have liver failure and obvious intrahepatic cholestasis, unless pre-existing advanced liver disease was present. The underlying mechanisms of liver injury in cases of COVID-19 might include psychological stress, systemic inflammation response, drug toxicity, and progression of pre-existing liver diseases. However, there is insufficient evidence for SARS-CoV-2 infected hepatocytes or virus-related liver injury in COVID-19 at present. The clinical, pathological and laboratory characteristics as well as underlying pathophysiology and etiology of liver injury in COVID-19 remain largely unclear. In this review, we highlight these important issues based on the recent developments in the field, for optimizing the management and treatment of liver injury in Chinese patients with COVID-19.
Gong Feng, Kenneth I. Zheng, Qin-Qin Yan, Rafael S. Rios, Giovanni Targher, Christopher D. Byrne, Sven Van Poucke, Wen-Yue Liu, Ming-Hua Zheng
Journal of Clinical and Translational Hepatology, Volume 8, pp 1-7; doi:10.14218/jcth.2020.00018

The outbreak of coronavirus disease 2019 (COVID-19), caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has attracted increasing worldwide attention. Cases of liver damage or dysfunction (mainly characterized by moderately elevated serum aspartate aminotransferase levels) have been reported among patients with COVID-19. However, it is currently uncertain whether the COVID-19-related liver damage/dysfunction is due mainly to the viral infection per se or other coexisting conditions, such as the use of potentially hepatotoxic drugs and the coexistence of systemic inflammatory response, respiratory distress syndrome-induced hypoxia, and multiple organ dysfunction. Based on the current evidence from case reports and case series, this review article focuses on the demographic and clinical characteristics, potential mechanisms, and treatment options for COVID-19-related liver dysfunction. This review also describes the geographical and demographic distribution of COVID-19-related liver dysfunction, as well as possible underlying mechanisms linking COVID-19 to liver dysfunction, in order to facilitate future drug development, prevention, and control measures for COVID-19.
Anand V Kulkarni, Pramod Kumar, Mithun Sharma, T R Sowmya, Rupjyoti Talukdar, Padaki Nagaraj Rao, D Nageshwar Reddy
Journal of Clinical and Translational Hepatology, Volume 8, pp 1-7; doi:10.14218/jcth.2019.00048

Cynthia J. Tsay, Joseph K. Lim
Journal of Clinical and Translational Hepatology, Volume 8, pp 1-17; doi:10.14218/jcth.2019.00059

Chronic hepatitis C infection in the USA is a highly morbid condition and current guidelines recommend one-time screening among the birth cohort (1945-1965). Understanding strategies to optimize screening can help inform future hepatitis C virus (HCV) screening guidelines. A focused literature search was performed using PubMed and manual abstract review from major hepatology conferences over the past 2 years. The search strategy involved using Medical Subject Headings terms for hepatitis C, screening, birth cohort, baby boomers, and 1945-1965. The review was limited to data from the USA. A total of 327 articles were identified and 36 abstracts were included, with studies published between 2012-2019. Strategies including clinician education, electronic medical record alerts, reflex HCV RNA testing, point-of-care testing, multisite (outpatient, inpatient, emergency department, endoscopy suite) initiatives, direct patient solicitation, and utilization of non-physician providers have increased HCV screening rates. However, broad implementation remains less than optimal. Barriers include lack of patient acceptance to screening and engagement in the HCV care cascade. The Veterans Affairs Healthcare System has achieved higher birth cohort screening rates through an integrated approach requiring high-level engagement by leadership and institutional commitment. Multiple strategies for increasing birth cohort screening have been successful, but overall rates of HCV screening remain low. These strategies can inform public health efforts to implement emerging national recommendations for expansion of HCV screening to all U.S. adults age 18 or older.
Xueru Yin, Guorong Han, Hua Zhang, Mei Wang, Wenjun Zhang, Yunfei Gao, Mei Zhong, Xiaolan Wang, Xiaozhu Zhong, Guojun Shen, et al.
Journal of Clinical and Translational Hepatology, Volume 8, pp 1-8; doi:10.14218/jcth.2019.00057

Background and Aims: The World Health Organization (WHO) Western Pacific Region set a target of eliminating mother-to-child transmission (MTCT) of hepatitis B virus (HBV) by 2030. To assess the feasibility of this target in China, we carried out an epidemiological study to investigate the status quo of MTCT in the real-world setting.
Cyriac Abby Philips, Guruprasad Padsalgi, Rizwan Ahamed, Rajaguru Paramaguru, Sasidharan Rajesh, Tom George, Pushpa Mahadevan, Philip Augustine
Journal of Clinical and Translational Hepatology, Volume 8, pp 1-6; doi:10.14218/jcth.2019.00056

Panagiotis Trilianos, Adamantios Tsangaris, Augustine Tawadros, Vrushak Deshpande, Nikolaos Pyrsopoulos
Journal of Clinical and Translational Hepatology pp 1-4; doi:10.14218/jcth.2019.00038

Moinak Sen Sarma, Aathira Ravindranath
Journal of Clinical and Translational Hepatology pp 1-8; doi:10.14218/jcth.2019.00041

Artin Galoosian, Courtney Hanlon, Julia Zhang, Edward W. Holt, Kidist K. Yimam
Journal of Clinical and Translational Hepatology pp 1-12; doi:10.14218/jcth.2019.00049